S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
LON:DEST

Destiny Pharma (DEST) Share Forecast, Price & News

GBX 29.80
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
29.62
▼
30
50-Day Range
28
▼
36
52-Week Range
27
▼
61.85
Volume
188,723 shs
Average Volume
376,087 shs
Market Capitalization
£28.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesOptions Chain

DEST stock logo

About Destiny Pharma (LON:DEST) Stock

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

Receive DEST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Destiny Pharma and its competitors with MarketBeat's FREE daily newsletter.

DEST Stock News Headlines

May 28, 2023 | americanbankingnews.com
Destiny Pharma plc (LON:DEST) Insider Nick Rodgers Acquires 49,477 Shares
May 25, 2023 | marketwatch.com
Destiny Pharma CEO Steps Down; Debra Barker Named as Interim Replacement
June 3, 2023 | Legacy Research (Affiliate) (Ad)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
May 25, 2023 | proactiveinvestors.com
Destiny Pharma chief steps down
May 2, 2023 | proactiveinvestors.com
Destiny Pharma's C.diffcile treatment on path to commercial success
May 2, 2023 | marketwatch.com
Destiny Pharma Gets Positive Results For Covid-19 Nasal Spray
May 2, 2023 | proactiveinvestors.com
Destiny Pharma reveals significant progress with Covid and flu spray
May 2, 2023 | proactiveinvestors.com
Destiny Pharma's nasal spray project already delivering "more than hoped for"
June 3, 2023 | Legacy Research (Affiliate) (Ad)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
April 18, 2023 | proactiveinvestors.com
Destiny Pharma says XF-73 now "very well positioned" for a partnering programme
April 16, 2023 | americanbankingnews.com
Destiny Pharma's (DEST) "House Stock" Rating Reiterated at Shore Capital
April 14, 2023 | proactiveinvestors.com
Destiny Pharma's almost 1,000% upside target reiterated by finnCap
April 13, 2023 | proactiveinvestors.com
Destiny Pharma focused on delivering further deals
April 6, 2023 | proactiveinvestors.com
Destiny Pharma upbeat on prospects for C. Difficile treatment
April 5, 2023 | proactiveinvestors.com
Destiny Pharma broker upbeat on latest data for key asset
April 4, 2023 | proactiveinvestors.com
Destiny Pharma hails latest peer-reviewed research on CDI asset
March 27, 2023 | americanbankingnews.com
Destiny Pharma (LON:DEST) Earns "House Stock" Rating from Shore Capital
March 24, 2023 | proactiveinvestors.com
Destiny Pharma looking to move on to phase III with XF-73 nasal gel
March 24, 2023 | proactiveinvestors.com
Destiny Pharma nasal gel results showcased in leading journal
March 15, 2023 | marketwatch.com
Destiny Pharma Raised GBP340,000 via Open Offer; Missed GBP8 Mln Fundraising Target
March 6, 2023 | proactiveinvestors.com
Destiny Pharma "making real progress"
February 18, 2023 | finance.yahoo.com
Here's Why We're Not Too Worried About Destiny Pharma's (LON:DEST) Cash Burn Situation
February 17, 2023 | marketwatch.com
Burns Treatment Market 2023 Size Industry, Current Trends, Demand and Size Share Estimation by 2028 with Top Players
February 15, 2023 | finance.yahoo.com
Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update
February 10, 2023 | marketwatch.com
Burns Treatment Market Share Likely to Grow At a CAGR
February 4, 2023 | msn.com
Destiny's child
January 27, 2023 | finance.yahoo.com
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
See More Headlines

DEST Price History

DEST Company Calendar

Last Earnings
9/17/2020
Today
6/03/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:DEST
CUSIP
N/A
CIK
N/A
Web
www.destinypharma.com
Phone
+44-1273-704440
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-6,500,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-85.94%
Return on Assets
-56.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.57
Quick Ratio
11.10

Sales & Book Value

Annual Sales
£135,028.00
Price / Sales
210.23
Cash Flow
GBX 11.08 per share
Price / Cash Flow
2.69
Book Value
GBX 10 per share
Price / Book
2.98

Miscellaneous

Outstanding Shares
95,260,000
Free Float
N/A
Market Cap
£28.39 million
Optionable
Optionable
Beta
0.36

Key Executives

  • Mr. Neil Robert Clark (Age 60)
    CEO & Director
    Comp: $303k
  • Dr. William Guy Love (Age 60)
    Founder, Chief Scientific Officer & Director
    Comp: $252k
  • Mr. Shaun Claydon ACA (Age 55)
    CFO, Company Sec. & Director
    Comp: $271k
  • Dr. Stephanie Bewick
    Chief Bus. Officer
  • Dr. Yuri Martina M.B.A.
    M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













DEST Stock - Frequently Asked Questions

How have DEST shares performed in 2023?

Destiny Pharma's stock was trading at GBX 53.50 at the beginning of the year. Since then, DEST stock has decreased by 44.3% and is now trading at GBX 29.80.
View the best growth stocks for 2023 here.

How were Destiny Pharma's earnings last quarter?

Destiny Pharma plc (LON:DEST) posted its earnings results on Thursday, September, 17th. The company reported ($5.50) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Destiny Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Dynavax Technologies (DVAX), AFPO.L (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB) and EQTEC (EQT).

What is Destiny Pharma's stock symbol?

Destiny Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DEST."

How do I buy shares of Destiny Pharma?

Shares of DEST stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Destiny Pharma's stock price today?

One share of DEST stock can currently be purchased for approximately GBX 29.80.

How much money does Destiny Pharma make?

Destiny Pharma (LON:DEST) has a market capitalization of £28.39 million and generates £135,028.00 in revenue each year. The company earns £-6,500,000.00 in net income (profit) each year or GBX (0.09) on an earnings per share basis.

How can I contact Destiny Pharma?

Destiny Pharma's mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The official website for the company is www.destinypharma.com. The company can be reached via phone at +44-1273-704440.

This page (LON:DEST) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -